Fahd Syed, MD
Nephrology · Columbus, GANPI 1770895419
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,363 of the $2,774 with a category attached, or 85.2%. It is spread thinly across 23 manufacturers, the largest accounting for just 17.9% — the pattern of someone who eats at a lot of different presentations.
Across 132 payments — averaging $21.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$495
- OPKO Pharmaceuticals, LLC$401
- Amgen$309
- Ardelyx, Inc.$228
- Akebia Therapeutics Inc$199
- Calliditas Therapeutics US Inc.$166
- plus $975 from 17 others
Across 1 payment — averaging $45,278 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$45K
What the payments were for
- Speaking & faculty fees$1505%
- Food & beverage$2,36385%
- Education$2619%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 15 | $495 |
| OPKO Pharmaceuticals, LLC | 27 | $401 |
| Amgen(2 entities) | 11 | $309 |
| Ardelyx, Inc. | 10 | $228 |
| Akebia Therapeutics Inc | 10 | $199 |
| Calliditas Therapeutics US Inc. | 2 | $166 |
| Travere Therapeutics, Inc. | 18 | $116 |
| Otsuka America Pharmaceutical, Inc. | 5 | $106 |
| Novartis | 4 | $94 |
| Abbott | 4 | $93 |
| Abiomed | 2 | $75 |
| Fresenius USA Marketing, Inc. | 4 | $74 |
| Novo Nordisk | 2 | $56 |
| Vifor Pharma, Inc. | 3 | $51 |
| Lilly USA, LLC | 3 | $48 |
| Fresenius USA Manufacturing, Inc. | 2 | $45 |
| GSK | 2 | $42 |
| Lemaitre Vascular, Inc. | 2 | $36 |
| Cormedix Inc. | 1 | $34 |
| Aurinia Pharma U.S., Inc. | 1 | $28 |
| Mallinckrodt Enterprises LLC | 2 | $27 |
| Chiesi USA, Inc. | 1 | $26 |
| Scpharmaceuticals Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,774 in reported general payments places this provider in the 60th percentile of 388 nephrology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 51 | $175,635 |
| XphozahTenapanor Hcl | 16 | $53,486 |
| KerendiaFinerenone | 22 | $32,612 |
| Sevelamer Carbonate | 94 | $26,082 |
| Cinacalcet Hcl | 16 | $25,923 |
| FarxigaDapagliflozin Propanediol | 26 | $24,150 |
| AuryxiaFerric Citrate | 12 | $21,850 |
| Lanthanum Carbonate | 18 | $20,687 |
| JanuviaSitagliptin Phosphate | 23 | $12,675 |
| LokelmaSodium Zirconium Cyclosilicate | 13 | $12,572 |
| Nifedipine ErNifedipine | 94 | $2,635 |
| Potassium Chloride | 65 | $1,653 |
| Midodrine Hcl | 20 | $1,290 |
| Losartan Potassium | 131 | $1,289 |
| Hydralazine Hcl | 91 | $1,283 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $74 | $175,63551 claims |
| AstraZenecaFarxiga, Lokelma | $495 | $36,72239 claims |
| Akebia Therapeutics IncAuryxia | $199 | $21,85012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 388 nephrology providers in Georgia.
Other nephrology in Columbus
- Rajendran AlappanColumbus$87K
- Rajeev ChauhanColumbus$32K
- Sagar PanseMacon$542K
- Sheldon ShoreAtlanta$474K
- James TumlinLawrenceville$434K
- Salvatore ChillemiMarietta$287K
- Christina KleinAtlanta$137K
- Mary MuonekeAtlanta$119K
- Don WilliamsonAugusta$104K
- Frederic Rahbari OskouiAtlanta$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.